We hypothesise that the opioid system of patients with ME/CFS and FM is dysregulated and that OPRM1 epigenetic regulation, at least partially, drives this dysregulation and may account for poorer clinical outcomes. This evidence concerns the gene OPRM1 and myalgic encephalomeyelitis/chronic fatigue syndrome.